Cargando…

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

Detalles Bibliográficos
Autores principales:	Saraf, S., Brown, R. C., Hagar, R. W., Idowu, M., Osunkwo, I., Kalfa, T. A., Kuypers, F. A., Geib, J., Schroeder, P., Wu, E., Kelly, P., Telen, M. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429144/ http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87

Ejemplares similares

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: M., TELEN, et al.
Publicado: (2022)

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
por: Telen, M, et al.
Publicado: (2022)

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: T., COATES, et al.
Publicado: (2022)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial
por: Forsyth, Sanjeev, et al.
Publicado: (2022)

Pyridoxamine: another vitamin for sickle cell disease?
por: Telen, Marilyn J.
Publicado: (2020)

1495. Fluoroquinolone as an Alternative Regimen for Klebsiella pneumoniae Liver Abscess
por: Chuang, Chien, et al.
Publicado: (2019)

Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients
por: Gutierrez, Mario, et al.
Publicado: (2021)

Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management
por: Ballas, Samir K., et al.
Publicado: (2012)

SPD_1495 Contributes to Capsular Polysaccharide Synthesis and Virulence in Streptococcus pneumoniae
por: Zheng, Yun-Dan, et al.
Publicado: (2020)

Biomarkers and recent advances in the management and therapy of sickle cell disease
por: Telen, Marilyn J.
Publicado: (2015)

Erratum to “Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management”
por: Ballas, Samir K., et al.
Publicado: (2013)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

Sex differences in progression of kidney disease in sickle cell disease
por: Ataga, Kenneth I., et al.
Publicado: (2022)

1495 Resistance of Fluoroquinolone in Orientia tsutsugamushi Due to gyrA Mutation in Scrub typhus
por: CHO, Soo Kyung, et al.
Publicado: (2014)

1495. Aspergillosis Complicating Severe Influenza in ICU Patients: A Retrospective Cohort Study
por: Visek, Caitlin, et al.
Publicado: (2020)

Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
por: Wun, Ted, et al.
Publicado: (2014)

Intrapartum Management of Sickle Cell Anemia With Rare Antibody and Minimal Blood Availability
por: Dom, Aaron M., et al.
Publicado: (2020)

1495. Incidence of Sexually Transmitted Infections (STIs) in Patients on Pre-exposure Prophylaxis (PrEP)
por: Hamed, Almutase, et al.
Publicado: (2018)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2020)

The Genomic Analysis of Erythrocyte microRNA Expression in Sickle Cell Diseases
por: Chen, Shao-Yin, et al.
Publicado: (2008)

Elastic property of sickle cell anemia and sickle cell trait red blood cells
por: Muhammed, Endris, et al.
Publicado: (2021)

1495. Mpox Vaccine Immunity in People Living with HIV (PLWH) During The 2022 Mpox Outbreak in New York City
por: Kottkamp, Angelica C, et al.
Publicado: (2023)

P-004: HEALTH CARE TRANSITION (HCT) FOR SICKLE CELL DISEASE (SCD) CAN BE STANDARDIZED: RESULTS OF IMPLEMENTING A SCD HCT LEARNING COLLABORATIVE.
por: I., OSUNKWO, et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
por: Saraf, Santosh L., et al.
Publicado: (2019)

Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies
por: Yilmaz, Ömer, et al.
Publicado: (2016)

Red cell transfusion and alloimmunization in sickle cell disease
por: Linder, Grace E., et al.
Publicado: (2021)

Red blood cell transfusion in sickle cell disease
por: Uminski, Kelsey, et al.
Publicado: (2023)

Validation of a novel point of care testing device for sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2015)

Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2022)

THE SPECIFIC HEAT AND THE HEAT OF COMPRESSION OF HUMAN RED CELLS, SICKLED RED CELLS, AND PARACRYSTALLINE RAT RED CELLS
por: Ponder, Eric
Publicado: (1955)

P-036: PIEZO1 ACTIVATION AUGMENTS SICKLING PROPENSITY AND THE ADHESIVE PROPERTIES OF SICKLE RED BLOOD CELLS
por: N., CONRAN, et al.
Publicado: (2022)

Automated Red Cell Exchange in the Management of Sickle Cell Disease
por: Tsitsikas, Dimitris A., et al.
Publicado: (2021)

Time to rethink haemoglobin threshold guidelines in sickle cell disease
por: Ballas, Samir K., et al.
Publicado: (2021)

Clonal hematopoiesis in sickle cell disease
por: Liggett, L. Alexander, et al.
Publicado: (2022)

Characterization of an interplay between a Mycobacterium tuberculosis MazF homolog, Rv1495 and its sole DNA topoisomerase I
por: Huang, Feng, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2j5o784iaj19uh894eksecbke2